Board of Directors
Hannu Ryöppönen, Member of the board
Mr Ryöppönen was, until 2009, CFO and deputy CEO in Stora Enso Oyj, FI. Before that he was CFO and executive in Royal Ahold, NL from 2003 to 2005 and served on the Board of Directors of the ICA Group, SE, including the chairmanship of the audit committee.
From 1999 to 2003, Mr Ryöppönen was Finance Director of Industri Kapital Group, UK. Mr Ryöppönen served as CFO of the IKEA Group, Denmark, from 1985 to 1998, including a position as deputy CEO of IKANO Asset Management from 1998 to 1999. From 1977 to 1985, Mr Ryöppönen held various management positions at Chemical Bank in the US and the UK, as well as for Alfa Laval in the US and Sweden.
Mr Ryöppönen is chairman of BillerudKornäs AB, Sweden, and a member of the boards of Amer Sports Oyj, Finland, and the private equity fund Value Creation Investments Limited, Jersey, Channel Islands. Mr Ryöppönen is also chairman of the audit committee of Amer Sports Oyj, Finland. Finally, Mr Ryöppönen is chairman of the boards of private equity funds, Altor 2003 GP Limited, Altor Fund II GP Limited and Altor III GP Limited, Jersey, Channel Islands.
Mr Ryöppönen has a BA in Business Administration from Hanken School of Economics, Helsinki, Finland, from 1976.
Mr Ryöppönen was first elected to the Board of Novo Nordisk A/S in 2009 and has most recently been re-elected in March 2014. His term as a board member expires in March 2015.
In March 2014, the Board of Directors of Novo Nordisk A/S assessed that Mr Ryöppönen is regarded as an independent board member as defined in Section 3.2.1 of the Recommendations on Corporate Governance designated by NASDAQ Copenhagen (2013).
In March 2009, the Board of Directors of Novo Nordisk A/S elected Mr Ryöppönen as member of the Audit Committee and designated him as financial expert under both Danish law and US Securities and Exchange Commission (the "SEC") rules. In March 2012, the Board of Directors elected Mr Ryöppönen as chairman of the Audit Committee at Novo Nordisk A/S.
In March 2014, the Board of Directors of Novo Nordisk A/S assessed that Mr Ryöppönen is regarded as independent under SEC rules and is regarded as independent under part 8 of the Danish Act on Approved Auditors and Audit firms.
In January 2014, the Board of Directors also assessed that the special competences possessed by Mr Ryöppönen that are important for the performance of his duties are his international executive background and thorough understanding of managing finance operations in global organisations, in particular in relation to accounting, financial and capital markets issues, but also his experience within private equity and Mergers & Acquisitions (M&A).
Mr Ryöppönen is a male Finnish national, born March 1952.